Amgen shares are trading lower amid sympathy with Novartis after that company's pelacarsen phase III trial failed to reach its primary endpoint, with investors assessing the impact on AMGN's olpasiran phase III study. Also, BMO Capital downgraded its rating on the stock from Outperform to Market Perform and maintained its $450 price target.